Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)
Status:
Completed
Trial end date:
2016-06-06
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the efficacy and safety of afamelanotide, when
combined with narrowband ultraviolet B (NB-UVB) phototherapy, in patients with nonsegmental
vitiligo. Afamelanotide is expected to increase the rate of the repigmentation induced by
NB-UVB, leading to a reduced frequency and dose of NB-UVB.